LALPATHLAB.NSE · Dr. Lal PathLabs Limited

-

Please sign in to comment on LALPATHLAB.NSE

1 Comment

Admin

4 years ago

Dr. Lal PathLabs Limited is currently in a long term uptrend where the price is trading 36.3% above its 200 day moving average.

From a valuation standpoint, the stock is 244.6% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 16.5.

Dr. Lal PathLabs Limited's total revenue rose by 38.0% to $5B since the same quarter in the previous year.

Its net income has increased by 74.7% to $945M since the same quarter in the previous year.

Based on the above factors, Dr. Lal PathLabs Limited gets an overall score of 3/5.

Industry	Diagnostics & Research
Exchange	NSE
CurrencyCode	INR
ISIN	INE600L01024
Sector	Healthcare

Target Price	3085.913
Market Cap	232B
Dividend Yield	1.3%
PE Ratio	55.24
Beta	0.26

ABOUT

Dr. Lal PathLabs Limited

Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers training programs. The company was founded in 1949 and is based in Gurugram, India.

LALPATHLAB.NSE · Dr. Lal PathLabs Limited

-

Dr. Lal PathLabs Limited

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Dr. Lal PathLabs Limited using a moving average strategy